Armata Pharmaceuticals, Inc. (ARMP)
NYSEAMERICAN: ARMP · Real-Time Price · USD
2.250
-0.120 (-5.06%)
At close: May 20, 2025, 4:00 PM
2.180
-0.070 (-3.11%)
Pre-market: May 21, 2025, 4:15 AM EDT
Armata Pharmaceuticals Revenue
Armata Pharmaceuticals had revenue of $491.00K in the quarter ending March 31, 2025, a decrease of -49.17%. This brings the company's revenue in the last twelve months to $4.70M. In the year 2024, Armata Pharmaceuticals had annual revenue of $5.17M with 14.24% growth.
Revenue (ttm)
$4.70M
Revenue Growth
+14.24%
P/S Ratio
17.32
Revenue / Employee
$78,317
Employees
60
Market Cap
81.41M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ARMP News
- 1 day ago - Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia - PRNewsWire
- 6 days ago - Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update - PRNewsWire
- 19 days ago - Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 - PRNewsWire
- 2 months ago - Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update - PRNewsWire
- 2 months ago - Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva - PRNewsWire
- 2 months ago - Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit - PRNewsWire
- 5 months ago - Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection - PRNewsWire
- 6 months ago - Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting - PRNewsWire